Metformina Pharmconsul (Metformin Hydrochloride)

Metformin Hydrochloride primarily inhibits hepatic gluconeogenesis, which reduces the amount of glucose released by the liver. It also activates AMP‑activated protein kinase, enhancing glucose uptake in muscle and fat cells while decreasing intestinal glucose absorption, collectively improving overall blood sugar control.

The dosage of Metformina Pharmconsul is individualized. A qualified prescriber determines the appropriate strength, frequency, and titration schedule based on the patient’s renal function, glycaemic targets, and tolerability. Patients should follow the prescribing information provided by their healthcare professional.

Metformina Pharmconsul falls under an unknown pregnancy category. It should be used during pregnancy only if the potential benefit outweighs any possible risk to the fetus. Breastfeeding mothers should consult their physician, as metformin is excreted in breast milk and safety data are limited.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any required import documentation.

Metformina Pharmconsul (metformin) belongs to the biguanide class and is generally first‑line therapy for type 2 diabetes because it does not cause weight gain and has a low risk of hypoglycaemia when used alone. Compared with sulfonylureas, it has a more favourable safety profile, and unlike insulin, it is administered orally.

Metformina Pharmconsul should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Metformina Pharmconsul is taken orally as a tablet, usually with meals to minimise gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water; it is not intended for crushing, chewing, or splitting unless specifically advised by a healthcare professional.

The most serious adverse reactions include lactic acidosis, a rare but life‑threatening condition, especially in patients with renal or hepatic impairment. Severe hypoglycaemia can occur when metformin is combined with insulin or sulfonylureas. Long‑term therapy may also lead to vitamin B12 deficiency, which should be monitored periodically.

Metformina Pharmconsul is contraindicated in individuals with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in patients with known hypersensitivity to metformin or any component of the formulation.